跳至主要内容
临床试验/NCT04432155
NCT04432155Unknown2 期

A Double-Blind, Randomized, Placebo-Controlled Trial of Xenon Inhalation for Treatment of Patients With Panic Disorder

Nobilis Therapeutics Inc.0 个研究点目标入组 200 人开始时间: 2021年6月最近更新:
适应症
干预措施

试验速览

阶段
2 期
入组人数
200
主要终点
PDSS

研究概览

简要总结

This study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with panic disorder.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Primary diagnosis of panic disorder according to DSM-
  • Male and female patients ≥18 years of age.

排除标准

  • History of schizophrenia, bipolar and other psychotic disorders.
  • Patients with underlying pulmonary disease, chronic obstructive pulmonary disease (COPD), asthma, severe lung disease and/or baseline oxygen saturations <92% or any other respiratory conditions / diseases that may affect the respiratory function.
  • Currently undergoing targeted empirically-driven psychotherapy for panic disorder or panic disorder-related symptoms.
  • Currently undergoing exposure-based psychotherapy for any condition.

研究组 & 干预措施

Placebo

Placebo Comparator

Combination Product: Placebo The placebo medical gas consists of 30% oxygen and 70% nitrogen. The dose of placebo medical gas is 10 L by volume.

干预措施: Placebo (Drug)

NBTX-001

Experimental

Combination Product: NBTX-001 Xenon Inhaler The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.

干预措施: Xenon (Drug)

结局指标

主要结局

PDSS

时间窗: Baseline to Week 6

Panic Disorder Severity Scale

次要结局

  • PHQ-9(Baseline to Week 6)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Xenon Inhalation for Treatment of Panic Disorder | 临床试验